SEPNSepterna, Inc.
Is the price fair?
Modest expectations priced in. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for ~2% a year FCF growth. The price bakes in little to no growth.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What SEPN's price assumes
Septerna, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 15.7× revenue.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 6.8%
Free cash flow yield · Biotechnology median 3.6%
- Growth the price implies
- +1.7%
Growth the price implies · What free cash flow would have to do every year for a decade to justify today's price, discounted at 9.0%.
- Price / book
- 4.02
Price / book · as of 2026-Q2
Details›
- Price / bookas of 2026-Q2
- 4.02
- EV / EBIToperating margin −44%: the multiple describes the denominator
- not meaningful
- Free cash flow, trailing twelve months
- $105M
- Market capitalisation
- $1.56B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Biotechnology
The closest names by size in the same industry